secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001493152-23-006504
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered
--------------------------------------------------------------------------------

- Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).
- Cash $6.4M as of Dec 31, 2022; expects to fund operations into Q3 2023.
- Phase III TIGeR-PaC trial: first interim analysis triggered after 26 events (30% of 86); DMC review underway; results expected within a week.
- 47 of 114 target patients randomized; second interim analysis expected in 2024.
- Operating expenses $10.0M, up from $5.7M; R&D $4.3M, G&A $5.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/0001493152-23-006504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer